Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Meridian Bioscience Inc is a diagnostics & research business based in the US. Meridian Bioscience shares (VIVO) are listed on the NASDAQ and all prices are listed in US Dollars. Meridian Bioscience employs 750 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$18.25|
|52-week range||$15.45 - $30.65|
|50-day moving average||$19.43|
|200-day moving average||$20.49|
|Wall St. target price||$26.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.62|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||0.83%|
|1 month (2021-09-17)||-8.75%|
|3 months (2021-07-16)||0.66%|
|6 months (2021-04-16)||-21.51%|
|1 year (2020-10-16)||0.97%|
|2 years (2019-10-18)||81.95%|
|3 years (2018-10-18)||17.29%|
|5 years (2016-10-18)||18.65|
Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Meridian Bioscience shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $109.4 million.
The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$305.8 million|
|Operating margin TTM||30.75%|
|Gross profit TTM||$156.2 million|
|Return on assets TTM||13.57%|
|Return on equity TTM||25.65%|
|Market capitalisation||$791.2 million|
TTM: trailing 12 months
There are currently 3.1 million Meridian Bioscience shares held short by investors – that's known as Meridian Bioscience's "short interest". This figure is 10% down from 3.4 million last month.
There are a few different ways that this level of interest in shorting Meridian Bioscience shares can be evaluated.
Meridian Bioscience's "short interest ratio" (SIR) is the quantity of Meridian Bioscience shares currently shorted divided by the average quantity of Meridian Bioscience shares traded daily (recently around 258904.49152542). Meridian Bioscience's SIR currently stands at 11.8. In other words for every 100,000 Meridian Bioscience shares traded daily on the market, roughly 11800 shares are currently held short.
However Meridian Bioscience's short interest can also be evaluated against the total number of Meridian Bioscience shares, or, against the total number of tradable Meridian Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Meridian Bioscience's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Meridian Bioscience shares in existence, roughly 70 shares are currently held short) or 0.0708% of the tradable shares (for every 100,000 tradable Meridian Bioscience shares, roughly 71 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Meridian Bioscience.
Find out more about how you can short Meridian Bioscience stock.
We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.
Meridian Bioscience's shares were split on a 3:2 basis on 13 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.
Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $15.45 up to $30.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.4942. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).
Meridian Bioscience, Inc. , a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.